5owp
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Crystal structure of glycopeptide "GVTSAfPDT*RPAP" in complex with scFv-SM3== | |
+ | <StructureSection load='5owp' size='340' side='right' caption='[[5owp]], [[Resolution|resolution]] 1.85Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[5owp]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5OWP OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5OWP FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=A2G:N-ACETYL-2-DEOXY-2-AMINO-GALACTOSE'>A2G</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr> | ||
+ | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=4FB:(4S)-4-FLUORO-L-PROLINE'>4FB</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5owp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5owp OCA], [http://pdbe.org/5owp PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5owp RCSB], [http://www.ebi.ac.uk/pdbsum/5owp PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5owp ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | A structure-based design of a new generation of tumor-associated glycopeptides with improved affinity against two anti-MUC1 antibodies is described. These unique antigens feature a fluorinated proline residue, such as a (4S)-4-fluoro-l-proline or 4,4-difluoro-l-proline, at the most immunogenic domain. Binding assays using biolayer interferometry reveal 3-fold to 10-fold affinity improvement with respect to the natural (glyco)peptides. According to X-ray crystallography and MD simulations, the fluorinated residues stabilize the antigen-antibody complex by enhancing key CH/pi interactions. Interestingly, a notable improvement in detection of cancer-associated anti-MUC1 antibodies from serum of patients with prostate cancer is achieved with the non-natural antigens, which proves that these derivatives can be considered better diagnostic tools than the natural antigen for prostate cancer. | ||
- | + | The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer.,Somovilla VJ, Bermejo IA, Albuquerque IS, Martinez-Saez N, Castro-Lopez J, Garcia-Martin F, Companon I, Hinou H, Nishimura SI, Jimenez-Barbero J, Asensio JL, Avenoza A, Busto JH, Hurtado-Guerrero R, Peregrina JM, Bernardes GJL, Corzana F J Am Chem Soc. 2017 Dec 12. doi: 10.1021/jacs.7b09447. PMID:29166012<ref>PMID:29166012</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | <div class="pdbe-citations 5owp" style="background-color:#fffaf0;"></div> | |
- | + | == References == | |
- | + | <references/> | |
- | [[Category: | + | __TOC__ |
- | [[Category: Asensio, J | + | </StructureSection> |
- | + | [[Category: Albuquerque, I S]] | |
+ | [[Category: Asensio, J L]] | ||
[[Category: Avenoza, A]] | [[Category: Avenoza, A]] | ||
- | [[Category: | + | [[Category: Bermejo, I A]] |
- | [[Category: | + | [[Category: Bernardes, G J]] |
- | [[Category: Busto, J | + | [[Category: Busto, J H]] |
+ | [[Category: Castro-Lopez, J]] | ||
[[Category: Corzana, F]] | [[Category: Corzana, F]] | ||
[[Category: Garcia-Martin, F]] | [[Category: Garcia-Martin, F]] | ||
- | [[Category: | + | [[Category: Hinou, H]] |
[[Category: Hurtado-Guerrero, R]] | [[Category: Hurtado-Guerrero, R]] | ||
+ | [[Category: Jimenez-Barbero, J]] | ||
[[Category: Martinez-Saez, N]] | [[Category: Martinez-Saez, N]] | ||
- | [[Category: | + | [[Category: Nishimura, S]] |
+ | [[Category: Peregrina, J M]] | ||
+ | [[Category: Somovilla, V J]] | ||
+ | [[Category: Immune system]] |
Revision as of 06:57, 13 December 2017
Crystal structure of glycopeptide "GVTSAfPDT*RPAP" in complex with scFv-SM3
|